NCT00999336

A Study to Determine the Pharmacokinetics, Pharmacodynamics, and Tolerabiltiy of Betrixaban in Patients With Mild, Moderate, and Severe Renal Impairment

Pharmacokinetics, Pharmacodynamics, and Tolerability of Betrixaban Administered Orally in Subjects With Normal and Reduced Renal Function.

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: Portola Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Accepted

Summary

The purpose of the study is to compare the pharmacokinetics, pharmacodynamics, and tolerability of betrixaban in patients with mild, moderate, and severe renal impairment to healthy volunteers.

Conditions

• Renal Impairment

Interventions

Type	Name	Description
DRUG	Betrixaban	80 mg betrixaban qd for 8 days

Timeline

• Start date: 2009-07-31
• Primary completion: 2010-02-28
• Completion: 2010-02-28
• First posted: 2009-10-21
• Last updated: 2023-08-22
• Results posted: 2023-08-22

Locations

1 site across 1 country: Germany